SE8502950L - NEW GALENIC RETARD FORM - Google Patents

NEW GALENIC RETARD FORM

Info

Publication number
SE8502950L
SE8502950L SE8502950A SE8502950A SE8502950L SE 8502950 L SE8502950 L SE 8502950L SE 8502950 A SE8502950 A SE 8502950A SE 8502950 A SE8502950 A SE 8502950A SE 8502950 L SE8502950 L SE 8502950L
Authority
SE
Sweden
Prior art keywords
matrix
retard form
new galenic
percent
weight
Prior art date
Application number
SE8502950A
Other languages
Unknown language ( )
Swedish (sv)
Other versions
SE8502950D0 (en
SE504583C2 (en
Inventor
W Czarnecki
J C Gfeller
H P Bier
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8502950D0 publication Critical patent/SE8502950D0/en
Publication of SE8502950L publication Critical patent/SE8502950L/en
Publication of SE504583C2 publication Critical patent/SE504583C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A solid dispersion of a pharmacologically active agent in a crystalline matrix as a carrier is characterized by an agent which a. has a solubility of maximally 0.01% at 37 DEG C in water, b. is present in the matrix at a total concentration of more than 5 percent of weight, c. is present in the matrix at a concentration of above 5 percent by weight in a coherent crystalline form. The matrix can be a polyalkylene glycol and the active agent may be a dihydropyridine etc.
SE8502950A 1984-06-14 1985-06-13 New Galenic retard form SE504583C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3422083 1984-06-14
DE3442566 1984-11-22

Publications (3)

Publication Number Publication Date
SE8502950D0 SE8502950D0 (en) 1985-06-13
SE8502950L true SE8502950L (en) 1985-12-15
SE504583C2 SE504583C2 (en) 1997-03-10

Family

ID=25822108

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8502950A SE504583C2 (en) 1984-06-14 1985-06-13 New Galenic retard form

Country Status (21)

Country Link
AT (1) AT391806B (en)
AU (2) AU587190B2 (en)
BE (1) BE902626A (en)
CA (1) CA1264441A (en)
CY (1) CY1635A (en)
DE (1) DE3520184C2 (en)
DK (1) DK167649B1 (en)
ES (1) ES8702141A1 (en)
FR (1) FR2565822B1 (en)
GB (3) GB2160100B (en)
GR (1) GR851430B (en)
HK (1) HK25192A (en)
HU (1) HU198844B (en)
IE (1) IE58834B1 (en)
IL (1) IL75490A0 (en)
IT (1) IT1200080B (en)
LU (1) LU85946A1 (en)
NL (1) NL194389C (en)
NZ (1) NZ212390A (en)
PT (1) PT80635B (en)
SE (1) SE504583C2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (en) * 1985-10-15 1987-12-23 Eurand Spa PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
EP0406315B1 (en) * 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
GR1000270B (en) * 1988-09-30 1992-05-12 Alza Corp Dose for cardiovascular troubles therapy
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
MX9300110A (en) * 1992-01-13 1994-07-29 Gerhard Gergely PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENCE OR DISINTEGRATION TABLET OR OF AN INSTANT-TYPE GRANULATE AND PROCEDURE FOR ITS PREPARATION.
DE4201179A1 (en) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc.
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
WO1998001117A1 (en) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE19710009A1 (en) * 1997-03-12 1998-09-24 Knoll Ag Multi-phase preparation forms containing active ingredients
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
EP1189599A2 (en) * 1999-06-11 2002-03-27 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
JP3462490B2 (en) * 1999-08-04 2003-11-05 山之内製薬株式会社 Stable oral pharmaceutical composition
IL143375A0 (en) 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
CA2434835A1 (en) * 2001-02-13 2002-08-22 Astrazeneca Ab Novel modified released formulation
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (en) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent
WO2008070118A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
MX2011001864A (en) * 2008-08-20 2011-06-20 Univ Texas Hot-melt extrusion of modified release multi-particulates.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (en) * 1967-11-17 1971-03-25 Beiersdorf Ag Process for the production of medicaments with delayed release of active substances in the form of capsules
DE2400819C2 (en) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Process for the production of solid preparations of poorly soluble active pharmaceutical ingredients in extremely fine distribution
DE2546577B2 (en) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Solid substances made from polyvinylpyrrolidone and ergot alkaloids
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CH639659A5 (en) * 1978-12-18 1983-11-30 Sandoz Ag NEW 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE.
FI64938C (en) * 1977-06-20 1984-02-10 Sandoz Ag PROCEDURE FOR THE FRAMEWORK OF THERAPEUTIC THERAPEUTIC BENSOX A- AND OX BENZOTIADIAZOLYL-1,4-DIHYDROPYRID DERIVATIVES
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
DK154607C (en) * 1978-12-21 1989-06-05 Sandoz Ag PROCEDURE FOR PREPARING A PHARMACEUTICAL FORM FOR ORAL ADMINISTRATION OF ERGOTAL KALOIDS
DE2904310A1 (en) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh MOLDINGS WITH RETARDED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (en) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen SOLID PHARMACEUTICAL PREPARATIONS CONTAINING NIFEDIPINE AND METHOD FOR THE PRODUCTION THEREOF
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3318649A1 (en) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen TWO-PHASE FORMULATION

Also Published As

Publication number Publication date
GB8727056D0 (en) 1987-12-23
SE8502950D0 (en) 1985-06-13
HU198844B (en) 1989-12-28
GB8514855D0 (en) 1985-07-17
FR2565822B1 (en) 1989-02-17
GB2196852A (en) 1988-05-11
BE902626A (en) 1985-12-10
NL194389B (en) 2001-11-01
NL194389C (en) 2002-03-04
PT80635A (en) 1985-07-01
ATA174885A (en) 1990-06-15
PT80635B (en) 1987-10-20
SE504583C2 (en) 1997-03-10
CA1264441A (en) 1990-01-16
LU85946A1 (en) 1986-01-24
GB2160100A (en) 1985-12-18
DE3520184C2 (en) 1997-03-13
GB2196852B (en) 1989-05-17
DK167649B1 (en) 1993-12-06
DK264785D0 (en) 1985-06-12
ES8702141A1 (en) 1987-01-01
HK25192A (en) 1992-04-10
DE3520184A1 (en) 1985-12-19
GB8727055D0 (en) 1987-12-23
DK264785A (en) 1985-12-15
IE851460L (en) 1985-12-14
AU4348685A (en) 1985-12-19
GR851430B (en) 1985-11-25
GB2196851B (en) 1989-06-07
NZ212390A (en) 1992-02-25
CY1635A (en) 1992-11-06
IL75490A0 (en) 1985-10-31
IT8548210A0 (en) 1985-06-13
AT391806B (en) 1990-12-10
GB2196851A (en) 1988-05-11
GB2160100B (en) 1989-06-01
FR2565822A1 (en) 1985-12-20
IT1200080B (en) 1989-01-05
AU587190B2 (en) 1989-08-10
IE58834B1 (en) 1993-11-17
ES544075A0 (en) 1987-01-01
HUT40918A (en) 1987-03-30
NL8501578A (en) 1986-01-02
AU4454389A (en) 1990-03-22

Similar Documents

Publication Publication Date Title
SE8502950L (en) NEW GALENIC RETARD FORM
SE8603582D0 (en) COMPOSITION CONTAINING L-DOPA
EP0290442A4 (en) Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts.
NL300136I2 (en) Pharmacologically active catechol derivatives and their compositions.
CY1350A (en) Improvements in or relating to 3-aryloxy-3-phenylpropylamines
SE8701348D0 (en) IMPROVEMENTS IN PHARMACEUTICALLY ACCEPTABLE SALTS
SE8700137L (en) DIURETIC COMPOSITION
ATE59294T1 (en) STABILIZED MEDICATIONS.
IT8321497A0 (en) OPTICALLY ACTIVE OXALODIDINONE-2N-ARYLATE DERIVATIVES, SPECIFIC AND REVERSIBLE INHIBITORS OF TYPE B MONOAMINE OXIDASE AND THEIR PREPARATION PROCEDURE.
ATE50248T1 (en) AN IMIDAZOLIDINETRIONE DERIVATIVE OR A PHARMACEUTICAL COMPOSITION CONTAINING ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
ATE41602T1 (en) PARENTERAL COMPOSITION.
SE1214315T3 (en)
ATE31076T1 (en) SOLID STRONG ALKALINE AGENTS CONTAINING ACTIVE CHLORINE.
MY102425A (en) Preservative for wood
NO831293L (en) AMINOSYDPREPARATER
MY101902A (en) Novel galenical retard form
ES2122010T3 (en) AMYLINE MUTEINS.
JPS56109281A (en) Conditioner for heavy clay soil
CS274751B2 (en) Agent for plants' medium stress factors effects protection
AU6779487A (en) Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts
IT1224404B (en) ACTIVE COMPOUNDS ON THE CARDIOVASCULAR SYSTEM

Legal Events

Date Code Title Description
NUG Patent has lapsed